A Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Function at Varying Dosages in Healthy Younger Adults With Self-reported Attention Problems

Exclusion Criteria

• •1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
• •2. Allergy, sensitivity, or intolerance to the investigational product or placebo ingredients
• •3. Clinical diagnosis and/or prescribed treatment for ADHD (See Section 7.3.1)
• •4. Self-reported confirmation of any significant neuropsychological condition and/or cognitive impairment (e.g., Schizophrenia, bipolar disorder, post-traumatic stress disorder, brain injury, neurodegenerative disease, infections, insomnia, depression, epileptic or other seizure-related disorders) that could interfere with study participation as assessed by the QI
• •5. Self-reported color blindness/weakness as assessed by the QI
• •6. Individuals who consume high caffeine daily or are addicted to caffeine at screening as assessed by the QI
• •7. Current employment that calls for overnight shiftwork as assessed by the QI
• •8. Unstable metabolic disease or chronic diseases as assessed by the QI
• •9. Current or history of significant diseases of the gastrointestinal tract or conditions that result in malabsorption, as assessed by the QI
• •10. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (See Section 7.3.1)
• •11. Type I diabetes
• •12. Type II diabetes if on insulin treatment. Type II diabetics on stable medication for at least three months and an HbA1c of \<8.0% may be included after assessment by the QI on a case-by-case basis
• •13. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis
• •14. History of or current diagnosis with kidney, gallbladder (e.g., gallstones, bile duct obstruction), and/or liver diseases (e.g., reduced bile salts, SIBO) as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months
• •15. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
• •16. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI
• •17. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable
• •18. Individuals with an autoimmune disease or are immune compromised as assessed by the QI
• •19. Self-reported confirmation of a HIV-, Hepatitis B- and/or C-positive diagnosis as assessed by the QI
• •20. Self-reported confirmation of blood/bleeding disorders as assessed by QI
• •21. Use of medical cannabinoid products
• •22. Chronic use of cannabinoid products (\>2 times/week). Occasional users will be required to washout and abstain for the duration of the study period
• •23. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period
• •24. Alcohol intake average of \>2 standard drinks per day as assessed by the QI
• •25. Alcohol or drug abuse within the last 12 months
• •26. Current use of prescribed and/or OTC medications, supplements, and/or consumption of food/drinks that may impact the efficacy and/or safety of the investigational product (Sections 7.3.1 and 7.3.2)
• •27. Clinically significant abnormal laboratory results at screening as assessed by the QI
• •28. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit
• •29. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI
• •30. Individuals who are cognitively impaired and/or unable to give informed consent
• •31. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant